PRTX-100: Phase I/II started

Protalex began the open-label, U.S. Phase I/II PRTX-100-105 trial to evaluate 420 ug IV PRTX-100 weekly for 4 weeks in up to 12 patients who participated in the Phase Ib PRTX-100-104 trial and in 5 he...